There is a clear delineation between medical and recreational cannabis, but few people know what is required to produce pharmaceutically viable cannabis for clinical trials and research programs. This session will explore the key inputs pharmaceutical institutions are seeing when they engage in prospective clinical trials, including the importance of having the correct infrastructure, genetic diversity and formulations as well as promoting commercially structured plant-breeding programs.
You’ll get insights on:
- How growing in a controlled environment pertains to crop quality.
- The lack of genetic diversity in cannabis and the importance of structured plant-breeding programs.
- Why downstream formulations are the future of cannabis.